Hettie J.
- Country
- The Netherlands
- Department
- Department of Pediatrics, division of Respiratory Medicine and Allergology
Research Overview
- Long-term Safety and Efficacy Evaluation of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients Aged 12 Months and Older
- Phase 3 Open-Label Study on Pharmacokinetics, Safety, and Tolerability of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients Aged 12 to <24 Months
- Phase 3 Evaluation of Pharmacokinetics, Safety, and Tolerability of VX-121/Tezacaftor/Deutivacaftor Combination in Pediatric Cystic Fibrosis Patients
Data & Insights
Has run more than one trial at 7 of 15 partner sites.
Specializations
Pediatric Cystic Fibrosis Research
The investigator specializes in studying therapeutic interventions for cystic fibrosis in pediatric populations, with particular focus on patients ranging from 12 months to 11 years of age.
- Early childhood treatment evaluation
- Age-specific therapeutic approaches
- Pediatric drug safety assessment
Key interest in evaluating treatment responses in young children with cystic fibrosis.
Novel Therapeutic Combinations
Focuses on investigating innovative combination therapies for cystic fibrosis, including elexacaftor/tezacaftor/ivacaftor and vanzacaftor/tezacaftor/deutivacaftor treatments.
- Triple combination therapies
- Long-term efficacy studies
- Treatment tolerability assessment
Specializes in evaluating the safety profiles of multi-drug therapeutic approaches.
Long-term Treatment Outcomes
Dedicated to understanding the long-term safety and efficacy of cystic fibrosis treatments across different age groups, from infants to adults.
- Extended duration safety monitoring
- Cross-age group effectiveness
- Therapeutic sustainability assessment
Examines the prolonged impact of treatments on patient outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.